Today just over three per cent of pancreatic cancer patients survive for at least five years, only a fraction more than the two per cent who survived that long in the early 1970s. Across all cancers, half of patients now survive at least twice that long. But most cases of pancreatic cancer go undetected until it is too late for surgery. …
“It’s only ten percent that were classified differently, but it matters a lot if you’re one of those patients,” said senior author Josh Stuart, a professor of biomolecular engineering at UC Santa Cruz. Stuart helped organize the study as part of the Pan-Cancer Initiative of the Cancer Genome Atlas (TCGA) project…
Despite this new evidence for the effectiveness of prostate-specific antigen (PSA) testing to reduce mortality, doubts as to whether the benefits of screening outweigh the harms remain, and routine PSA screening programmes should not be introduced at this time, conclude the authors. The European Randomised study of Screening for Prostate Cancer (ERSPC) began in 1993 to determine whether screening men for PSA reduces deaths from prostate cancer. …
The varying health risks from exposure to natural uranium are well established, but Diane Stearns, professor of biochemistry at Northern Arizona University, and her team have been trying to determine if there is a link between uranium exposure and skin cancer, stating that skin may have been overlooked in the past. In a recent article published in the Journal of Applied Toxicology, the NAU team shared results from a study that explored photoactivation of uranium as a means to increase its toxicity and ability to damage DNA. …
Researchers have long known that chromosomal defects that occur as cells repeatedly divide over time are linked to the onset of cancer. …
The study, led by Queen May University of London (QMUL) and published today in the journal Cell Reports, discovered how many stem cells exist within the human bowel and how they behave and evolve over time. …
Despite this new evidence for the effectiveness of prostate-specific antigen (PSA) testing to reduce mortality, doubts as to whether the benefits of screening outweigh the harms remain, and routine PSA screening programmes should not be introduced at this time, conclude the authors. The European Randomised study of Screening for Prostate Cancer (ERSPC) began in 1993 to determine whether screening men for PSA reduces deaths from prostate cancer. …
In a study run through the international PALB2 Interest Group a team of researchers from 17 centres in eight countries led by the University of Cambridge analysed data from 154 families without BRCA1 or BRCA2 mutations, which included 362 family members with PALB2 gene mutations. The effort was funded by the European Research Council, Cancer Research UK and multiple other international sources. Women who carried rare mutations in PALB2 were found to have on average a 35% chance of developing breast cancer by the age of seventy…
“It’s only ten percent that were classified differently, but it matters a lot if you’re one of those patients,” said senior author Josh Stuart, a professor of biomolecular engineering at UC Santa Cruz. Stuart helped organize the study as part of the Pan-Cancer Initiative of the Cancer Genome Atlas (TCGA) project…
Some particularly enterprising cancer cells can cause a cancer to spread to other organs, called metastasis, or evade treatment to resurface after a patient is thought to be in remission. The Illinois team, along with colleagues in China, found that these so-called tumor-repopulating cells may lurk quietly in stiffer cellular environments, but thrive in a softer space. The results appear in the journal Nature Communications…